Clinical data | |
---|---|
Trade names | Egrifta |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611035 |
Routes of administration | Subcutaneous injection |
Drug class | Growth-hormone-releasing hormone (GHRH)[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ≤4%[2] |
Metabolism | Proteolysis |
Elimination half-life | 26–38 min |
Excretion | Kidney |
Chemical and physical data | |
Formula | C221H366N72O67S |
Molar mass | 5135.86 g·mol−1 |
3D model (JSmol) | |
| |
|
Tesamorelin, sold under the brand name Egrifta, is a medication used to treat HIV-associated lipodystrophy.[1] Specifically it is used for excess abdominal fat.[3] It is given by injection under the skin.[1]
Common side effects include joint pain, redness at the site of injection, and leg swelling.[1] Other side effects may include allergic reactions and cancer.[1] Use in pregnancy may harm the baby.[1] It is a manufactured form of growth-hormone-releasing hormone (GHRH).[1]
Tesamorelin was approved for medical use in the United States in 2010.[1] It is not approved in Europe.[3] In the United States it costs about 6,400 USD per month as of 2021.[4]
References
edit- ^ a b c d e f g h i j k "Tesamorelin". drugs.com. American Society of Health-System Pharmacists. Archived from the original on 19 January 2021. Retrieved 1 October 2021.
- ^ "Egrifta (tesamorelin for injection) for Subcutaneous Use. U.S. Full Prescribing Information" (PDF). EMD Serono, Inc. Archived (PDF) from the original on 18 December 2011. Retrieved 9 April 2016.
- ^ a b "Egrifta: Withdrawal of the marketing authorisation application". Archived from the original on 1 October 2021. Retrieved 1 October 2021.
- ^ "Egrifta Prices, Coupons and Patient Assistance Programs". drugs.com. Archived from the original on 19 January 2021. Retrieved 1 October 2021.